LON:INS Instem (INS) Share Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free INS Stock Alerts GBX 830 0.00 (0.00%) (As of 11/20/2023) Add Compare Share Share Today's Range 830▼ 83050-Day Range 830▼ 83052-Week Range 580▼ 835.56Volume3,800 shsAverage Volume85,542 shsMarket Capitalization£199.62 millionP/E Ratio5,928.57Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get Instem alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Instem Stock (LON:INS)Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.Read More INS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INS Stock News HeadlinesFebruary 13, 2024 | msn.comThe Wrap: Maternal healthcareFebruary 13, 2024 | msn.comINSTEM expands to include all North Dakota Native studentsMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.February 7, 2024 | msn.comCrisprBits' OmiCrisp Tracks Omicron-derived JN.1 Variant in Sewage Samples in BengaluruJanuary 31, 2024 | bizjournals.comAustin tech companies made 20 key hires in JanuaryJanuary 25, 2024 | finance.yahoo.comInstem Enables Clients to Leverage ICH S1B Weight of Evidence GuidelineJanuary 24, 2024 | msn.comScientists in Bengaluru discover means to tackle Covid-19 variantsJanuary 2, 2024 | finance.yahoo.comCDISC Names Chris Decker President and CEOMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 27, 2023 | msn.comBattling persistence in tuberculosis bacteriaDecember 27, 2023 | msn.comIISc finds way to battle persistence in TuberculosisDecember 14, 2023 | finance.yahoo.comCulture, Tradition, STEM and Learning on the LandNovember 28, 2023 | fortune.comSeven years after Elon Musk started The Boring Company, the company only has 2.4 miles of tunnel to show for itNovember 28, 2023 | msn.comNearly £40m raised by London and Cambridge autotech companiesNovember 27, 2023 | finance.yahoo.comInstem Now Part of ARCHIMED to Further Accelerate Growth and ImpactNovember 3, 2023 | msn.comBritish life sciences firm Instem faces crunch vote on £203m buyoutNovember 3, 2023 | msn.comInstem bosses' windfall as takeover squeaks throughOctober 26, 2023 | msn.comScientists crack reasons behind resilience of dengue-spreadersOctober 24, 2023 | finance.yahoo.comIs Now The Time To Put Instem (LON:INS) On Your Watchlist?October 18, 2023 | thetimes.co.ukAccept £200m private equity deal, Kin + Carta urges shareholdersOctober 8, 2023 | finance.yahoo.comInvestors in Instem (LON:INS) have seen impressive returns of 187% over the past five yearsSeptember 28, 2023 | uk.news.yahoo.comInstem's second-largest shareholder opposes deal with PE firm ArchimedSeptember 26, 2023 | thetimes.co.ukTakeover deal undervalues Instem, says big investorSeptember 15, 2023 | marketwatch.comInstem Swung to 1H Pretax Loss Amid Higher CostsSeptember 1, 2023 | thetimes.co.ukInstem board ‘absurd’ to back £203m bidSeptember 1, 2023 | msn.comALEX BRUMMER: Investors who shunned UKAugust 31, 2023 | finanznachrichten.deSamson Rock Capital LLP - Re-issue: Form 8.3 - Instem PlcSee More Headlines Receive INS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:INS CUSIPN/A CIKN/A Webwww.instem.com Phone+44-1785-825600FaxN/AEmployees500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.14 Trailing P/E Ratio5,928.57 Forward P/E Ratio17.83 P/E Growth1.89Net Income£3.34 million Net Margins5.50% Pretax MarginN/A Return on Equity6.35% Return on Assets4.62% Debt Debt-to-Equity Ratio3.47 Current Ratio0.95 Quick Ratio0.84 Sales & Book Value Annual Sales£61.63 million Price / Sales3.24 Cash FlowGBX 54.41 per share Price / Cash Flow15.25 Book ValueGBX 239 per share Price / Book3.47Miscellaneous Outstanding Shares24,050,000Free FloatN/AMarket Cap£199.62 million OptionableNot Optionable Beta0.42 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Phil J. Reason (Age 61)CEO & Executive Director Comp: $300kMr. Nigel John Goldsmith (Age 61)CFO, Secretary & Executive Director Comp: $166kMs. Marybeth ThompsonChief Operating OfficerDr. Gordon Smith BaxterChief Scientific OfficerMr. Mark Poggi M.B.A.Ph.D., Executive Vice President of Global SalesMs. Eve LeconteChief People & Culture OfficerMr. Mike HarwoodChief Product OfficerMr. Gregor GrantExecutive Vice President of Preclinical SolutionsMr. John LeveilleExecutive Vice President of Clinical Trial AccelerationMore ExecutivesKey CompetitorsKoothLON:KOOCranewareLON:CRWhVIVOLON:HVOOxford BiomedicaLON:OXBAlliance PharmaLON:APHView All Competitors INS Stock Analysis - Frequently Asked Questions How have INS shares performed in 2024? Instem's stock was trading at GBX 830 at the start of the year. Since then, INS shares have increased by 0.0% and is now trading at GBX 830. View the best growth stocks for 2024 here. What other stocks do shareholders of Instem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Instem investors own include Abeona Therapeutics (ABEO), ARCA biopharma (ABIO), Apollo Investment (AINV), Alico (ALCO), Corindus Vascular Robotics (CVRS), DSS (DSS), Evans Bancorp (EVBN), The LGL Group (LGL) and UQM Technologies (UQM). How do I buy shares of Instem? Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:INS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instem plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.